Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teva ...

Barclays lowered the firm’s price target on Teva (TEVA) to $26 from $28 and keeps an Overweight rating on the shares. The post-earnings selloff ...

UBS lowered the firm’s price target on Teva (TEVA) to $27 from $30 and keeps a Buy rating on the shares. UBS says the pullback on the stock ...

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

India's pharmaceutical industry is set for growth, driven by strong market players, global reputation, and evolving trends.

Alzheimer’s Therapeutics MarketThe global Alzheimer’s therapeutics market is projected to experience significant growth, with an expected valuation of USD 3,052.3 million in 2023. The market is ...